Results 131 to 140 of about 45,259 (260)

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Sparing Muscle While Losing Fat: A Narrative Review of Ketogenic Diets and Lean Mass Preservation During Weight Loss. [PDF]

Nutrients
Caturano A, Mocini E, Titi L, Leva F, Cannavaro D, Tarsitano MG, Conte C.   +6 more
europepmc   +1 more source

The association between Healthy Eating Index‐2020 and epilepsy: Insights based on NHANES from 2013 to 2018

Epileptic Disorders, EarlyView.
Abstract Background Epilepsy is a serious chronic brain disease. However, limited study is focused on the association between dietary pattern and epilepsy management. Hence, we aim to investigate the association between the Healthy Eating Index (HEI‐2020) and epilepsy odds.
Kun Yu, Yingxin Wang, Huaiqing Gao
wiley   +1 more source

Ketosis as a Treatment for Severe Mental Illness: A Critical Review of Preclinical and Clinical Data. [PDF]

Curr Treat Options Psychiatry
Oduguwa IO, Smith DJ, Mudra Rakshasa-Loots A.   +2 more
europepmc   +1 more source

Ketogenic diet for infantile epileptic spasms

Epilepsia Open, EarlyView.
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury, Anamika Choudhary, Andy Cheuk‐Him Ng, Cezar Gavrilovici   +3 more
wiley   +1 more source

Ultra‐Processed Food Intake and its Association With Eating Disorders: A Scoping Review

European Eating Disorders Review, EarlyView.
ABSTRACT Objective Ultra‐processed foods have been associated with adverse health outcomes, but their relationship with eating disorders remains unclear. This scoping review mapped the available evidence on the association between ultra‐processed food intake and eating disorders in adolescents and adults.
Marthina Streda Walker, Natália R. Figueiredo, Luana Cristina Lermen, Maria Laura da Costa Louzada, Ana Maria P. Feoli   +4 more
wiley   +1 more source

The Ketogenic Diet in the Prevention and Treatment of Hypertension (HTN). [PDF]

Biomedicines
Rodzeń Ł, Dyńka D, Rodzeń M, Karakuła-Juchnowicz H, Łojko D, Kraszewski S, Grzywacz Ż, Bikman B, Unwin J, Unwin D, Fazio S.   +10 more
europepmc   +1 more source

Eating Disorder Clinician Views About the Impact of Out‐of‐Home Calorie Labelling on Their Patients: A Qualitative Interview Study

European Eating Disorders Review, EarlyView.
ABSTRACT Objective Accumulating evidence suggests that people with eating disorders experience mainly negative impacts of out‐of‐home calorie labelling. This study explored eating disorder clinician perspectives on how such labels affect individuals with eating disorders, and their views on implementation of this policy.
Abinaya Nadarajah, Imogen Peebles, Fiona Duffy, Nora Trompeter, Ellen Maloney, Dasha Nicholls, Ulrike Schmidt, Lucy Serpell, Helen Sharpe, Tom Jewell   +9 more
wiley   +1 more source

Cardiometabolic trade-offs of carbohydrate- and fat-focused diets: a network meta-analysis of randomised clinical trials. [PDF]

Eur J Nutr
Nikitara K, Kontogianni MD, Haidich AB, Bountziouka V.   +3 more
europepmc   +1 more source

Short‐term clinical responses in horses and ponies treated with canagliflozin: A clinical field study

Equine Veterinary Journal, EarlyView.
Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom, Sanna Truelsen Lindåse, Monika Wartel, Johan Bröjer   +3 more
wiley   +1 more source